User: Guest  Login
Title:

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

Document type:
Clinical Trial; Journal Article; Article
Author(s):
Steimer, W; Zopf, K; von Amelunxen, S; Pfeiffer, H; Bachofer, J; Popp, J; Messner, B; Kissling, W; Leucht, S
Abstract:
BACKGROUND: Amitriptyline has been replaced in many countries by alternative and more expensive drugs based on claims of improved tolerability and toxicity and despite slightly reduced efficacy. Preliminary studies indicate that adverse effects could be linked to polymorphisms of drug-metabolizing enzymes, but information on their clinical impact remains scanty and includes mainly case reports. We conducted a prospective blinded two-center study seeking correlations between CYP2C19 and CYP2D6 ge...     »
Journal title abbreviation:
Clin Chem
Year:
2005
Journal volume:
51
Journal issue:
2
Pages contribution:
376-85
Language:
eng
Fulltext / DOI:
doi:10.1373/clinchem.2004.041327
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/15590749
Print-ISSN:
0009-9147
TUM Institution:
Institut für Klinische Chemie und Pathobiochemie; Klinik und Poliklinik für Psychiatrie und Psychotherapie
 BibTeX